Background In patients with type 2 diabetes, the effects ofintensive glucose control on vascular outcomes remain uncertain.
Methods We randomly assigned 11,140 patients with type 2 diabetesto undergo either standard glucose control or intensive glucosecontrol, defined as the use of gliclazide (modified release)plus other drugs as required to achieve a glycated hemoglobinvalue of 6.5% or less. Primary end points were composites ofmajor macrovascular events (death from cardiovascular causes,nonfatal myocardial infarction, or nonfatal stroke) and majormicrovascular events (new or worsening nephropathy or retinopathy),assessed both jointly and separately.
Results After a median of 5 years of follow-up, the mean glycatedhemoglobin level was lower in the intensive-control group (6.5%)than in the standard-control group (7.3%). Intensive controlreduced the incidence of combined major macrovascular and microvascularevents (18.1%, vs. 20.0% with standard control; hazard ratio,0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), aswell as that of major microvascular events (9.4% vs. 10.9%;hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarilybecause of a reduction in the incidence of nephropathy (4.1%vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006),with no significant effect on retinopathy (P=0.50). There wereno significant effects of the type of glucose control on majormacrovascular events (hazard ratio with intensive control, 0.94;95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes(hazard ratio with intensive control, 0.88; 95% CI, 0.74 to1.04; P=0.12), or death from any cause (hazard ratio with intensivecontrol, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia,although uncommon, was more common in the intensive-controlgroup (2.7%, vs. 1.5% in the standard-control group; hazardratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001).
Conclusions A strategy of intensive glucose control, involvinggliclazide (modified release) and other drugs as required, thatlowered the glycated hemoglobin value to 6.5% yielded a 10%relative reduction in the combined outcome of major macrovascularand microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy. (ClinicalTrials.gov number,NCT00145925
[ClinicalTrials.gov]
.)
Source Information
The members of the Writing Committee of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group are listed in the Appendix. This article (10.1056/NEJMoa0802987) was published at www.nejm.org on June 6, 2008.
Address reprint requests to Dr. Anushka Patel at the Cardiovascular Division, George Institute for International Health, University of Sydney, P.O. Box M201, Missenden Rd., Sydney, NSW 2050, Australia, or at apatel{at}george.org.au.
Intensive Glucose Control in Type 2 Diabetes
Jenny-Avital E. R., Luan F. L., Nguyen K., Tobey T. A., Parashar A., Byington R. P., Gerstein H. C., Friedewald W. T., Patel A., MacMahon S., Chalmers J.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1519-1521, Oct 2, 2008.
Correspondence
This article has been cited by other articles:
Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A.
(2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol
161: 1-9
[Abstract][Full Text]
van Biesen, W., Van Laecke, S., Vanholder, R.
(2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant
24: 2286-2287
[Full Text]
Morath, C., Zeier, M.
(2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant
24: 2026-2029
[Full Text]
Fonseca, V., Inzucchi, S. E., Ferrannini, E.
(2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care
32: 1344-1345
[Full Text]
Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium,
(2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc.
16: 446-456
[Abstract][Full Text]
Cefalu, W. T.
(2009). Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?. Diabetes
58: 1469-1470
[Full Text]
Kazempour-Ardebili, S., Lecamwasam, V. L., Dassanyake, T., Frankel, A. H., Tam, F. W.K., Dornhorst, A., Frost, G., Turner, J. J.O.
(2009). Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care
32: 1137-1142
[Abstract][Full Text]
Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., Rocchini, A., on behalf of the American Heart Association Exerci,
(2009). Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association. Circulation
119: 3244-3262
[Full Text]
The BARI 2D Study Group,
(2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM
360: 2503-2515
[Abstract][Full Text]
Montori, V. M., Fernandez-Balsells, M.
(2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED
150: 803-808
[Abstract][Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp
55: 580-582
[Full Text]
Wilson, G., Perry, T.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: NO. cfp
55: 581-583
[Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp
55: 584-588
[Full Text]
Wilson, G., Perry, T.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: NON. cfp
55: 585-588
[Full Text]
Nahas, R., Moher, M.
(2009). Complementary and alternative medicine for the treatment of type 2 diabetes. cfp
55: 591-596
[Abstract][Full Text]
Haynes, R B., Haynes, G. A
(2009). What does it take to put an ugly fact through the heart of a beautiful hypothesis?. Evid. Based Med.
14: 68-69
[Full Text]
Booth, G. L
(2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med.
14: 73-73
[Full Text]
Diener, H.-C., Weimar, C.
(2009). Update of secondary stroke prevention. Nephrol Dial Transplant
24: 1718-1724
[Full Text]
Bartnik, M., Cosentino, F.
(2009). Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. Eur Heart J
30: 1301-1304
[Full Text]
McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., Herman, W. H.
(2009). Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD). Diabetes Care
32: 971-976
[Abstract][Full Text]
Buse, J. B., Wolffenbuttel, B. H.R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., Martin, S. A.
(2009). DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care
32: 1007-1013
[Abstract][Full Text]
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., Fink, J. C.
(2009). Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. CJASN
4: 1121-1127
[Abstract][Full Text]
Goode, K M, John, J, Rigby, A S, Kilpatrick, E S, Atkin, S L, Bragadeesh, T, Clark, A L, Cleland, J G F
(2009). Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart
95: 917-923
[Abstract][Full Text]
Senador, D., Kanakamedala, K., Irigoyen, M. C., Morris, M., Elased, K. M.
(2009). Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol
94: 648-658
[Abstract][Full Text]
Griffin, S., Graffy, J.
(2009). New QOF glycaemia targets are achievable and evidence based. BMJ
338: b1915-b1915
[Full Text]
Gellad, W. F., Detsky, A. S., Choudhry, N. K.
(2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm
66: 864-867
[Full Text]
Verhaert, D., Thomas, J. D.
(2009). Dysglycemia and acute myocardial infarction the role of echocardiography.. J Am Coll Cardiol Img
2: 600-603
[Full Text]
Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A.
(2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant
24: 1663-1671
[Abstract][Full Text]
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A.
(2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes
58: 1229-1236
[Abstract][Full Text]
Brice, R.
(2009). A taxi driver with type 2 diabetes. BMJ
338: b1369-b1369
[Full Text]
Cheng, A. Y.Y., Leiter, L. A.
(2009). Cardiovascular risk and glycemic control. CMAJ
180: 907-908
[Full Text]
Riveline, J.-P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., Hadjadj, S.
(2009). Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant
0: gfp181v1-gfp181
[Abstract][Full Text]
Kahn, S. E.
(2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA
301: 1590-1592
[Full Text]
Nathan, D. M.
(2009). Progress in Diabetes Research--What's Next. JAMA
301: 1599-1601
[Full Text]
Sanz, J., Moreno, P. R., Fuster, V.
(2009). The year in atherothrombosis.. J Am Coll Cardiol
53: 1326-1337
[Full Text]
Van den Berghe, G., Mesotten, D., Vanhorebeek, I.
(2009). Intensive insulin therapy in the intensive care unit. CMAJ
180: 799-800
[Full Text]
Preis, S. R., Hwang, S.-J., Coady, S., Pencina, M. J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S.
(2009). Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. Circulation
119: 1728-1735
[Abstract][Full Text]
Olin, J. L., Spooner, L. M.
(2009). Introduction: Cardiovascular Therapeutics. Journal of Pharmacy Practice
22: 133-134
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Med.
14: 34-37
[Full Text]
Cochran, E.
(2009). U-500 Insulin: When More With Less Yields Success. Diabetes Spectr.
22: 116-122
[Full Text]
O'Connor, P. J., Sperl-Hillen, J. M.
(2009). The Role of Diabetes Educators in the Medical Home. Diabetes Spectr.
22: 124-126
[Full Text]
Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D.
(2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice
22: 179-193
[Abstract]
Nuzum, D. S., Merz, T.
(2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice
22: 135-148
[Abstract]
Younis, N., Soran, H., Hassanein, M.
(2009). Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM
102: 293-296
[Full Text]
de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C.-E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., Glasziou, P., Grobbee, D. E., MacMahon, S., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. J. Am. Soc. Nephrol.
20: 883-892
[Abstract][Full Text]
Chait, A., Bornfeldt, K. E.
(2009). Diabetes and atherosclerosis: is there a role for hyperglycemia?. J. Lipid Res.
50: S335-S339
[Abstract][Full Text]
The NICE-SUGAR Study Investigators,
(2009). Intensive versus Conventional Glucose Control in Critically Ill Patients. NEJM
360: 1283-1297
[Abstract][Full Text]
Kosiborod, M., Inzucchi, S. E., Krumholz, H. M., Masoudi, F. A., Goyal, A., Xiao, L., Jones, P. G., Fiske, S., Spertus, J. A.
(2009). Glucose Normalization and Outcomes in Patients With Acute Myocardial Infarction. Arch Intern Med
169: 438-446
[Abstract][Full Text]
Lehman, R., Krumholz, H. M
(2009). Tight control of blood glucose in long standing type 2 diabetes. BMJ
338: b800-b800
[Full Text]
Song, S. H, Gray, T. A
(2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease
9: 69-74
[Abstract]
Henske, J. A., Griffith, M. L., Fowler, M. J.
(2009). Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Clin. Diabetes
27: 72-76
[Full Text]
Raz, I., Wilson, P. W.F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., Jacober, S. J.
(2009). Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care
32: 381-386
[Abstract][Full Text]
Ceriello, A.
(2009). Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?. Diabetes Care
32: 521-522
[Full Text]
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., Service, F. J.
(2009). Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab.
94: 709-728
[Abstract][Full Text]
Davis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., Tate, D. B.
(2009). Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes. Diabetes
58: 701-709
[Abstract][Full Text]
Kassabian, S. G.
(2009). Hemoglobin A1c Testing, Board-Recertification Scores, and Treatment Outcomes. Arch Intern Med
169: 417-417
[Full Text]
Gerstein, H. C.
(2009). Dysglycemia and Cardiovascular Risk in the General Population. Circulation
119: 773-775
[Full Text]
Liew, G., Mitchell, P., Wong, T. Y
(2009). Systemic management of diabetic retinopathy. BMJ
338: b441-b441
[Full Text]
Horton, E. S.
(2009). Defining the role of basal and prandial insulin for optimal glycemic control.. J Am Coll Cardiol
53: S21-S27
[Abstract][Full Text]
O'Sullivan, E. P, Dinneen, S. F
(2009). Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years. Evid. Based Med.
14: 9-10
[Full Text]
Haneda, M., Morikawa, A.
(2009). Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant
24: 338-341
[Full Text]
Schernthaner, G.
(2009). Kidney disease in diabetology: lessons from 2008. Nephrol Dial Transplant
24: 396-399
[Full Text]
Ceriello, A., Ihnat, M. A., Thorpe, J. E.
(2009). The "Metabolic Memory": Is More Than Just Tight Glucose Control Necessary to Prevent Diabetic Complications?. J. Clin. Endocrinol. Metab.
94: 410-415
[Abstract][Full Text]
Eddy, D., Schlessinger, L., Kahn, R., Peskin, B., Schiebinger, R.
(2009). Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis. Diabetes Care
32: 361-366
[Abstract][Full Text]
Khanderia, U., Pop-Busui, R., Eagle, K.
(2009). Authors' Reply. The Annals of Pharmacotherapy
43: 392-393
[Full Text]
Havas, S.
(2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med
169: 150-154
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol
53: 298-304
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation
119: 351-357
[Full Text]
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., the VADT Investigators,
(2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM
360: 129-139
[Abstract][Full Text]
Bhattacharyya, O. K., Estey, E. A., Cheng, A. Y.Y.
(2009). Update on the Canadian Diabetes Association 2008 clinical practice guidelines. cfp
55: 39-43
[Full Text]
Grant, P. J
(2009). The EASD/ADA consensus: trick or treat?. Diabetes and Vascular Disease Research
6: 5-6
Lindsey, J. B, Cipollone, F., Abdullah, S. M, Mcguire, D. K
(2009). Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research
6: 7-14
[Abstract]
Gore, M O., McGuire, D. K
(2009). The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes and Vascular Disease Research
6: 53-55
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Nurs.
12: 4-6
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes
27: 4-16
[Full Text]
Sherifali, D.
(2009). Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 years. Evid. Based Nurs.
12: 14-14
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr.
22: 6-17
[Full Text]
Gulcelik, N. E., Karakaya, J., Gedik, A., Usman, A., Gurlek, A.
(2009). Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol
160: 65-70
[Abstract][Full Text]
Bott, D. M., Kapp, M. C., Johnson, L. B., Magno, L. M.
(2009). Disease Management For Chronically Ill Beneficiaries In Traditional Medicare. Health Aff (Millwood)
28: 86-98
[Abstract][Full Text]
Singh, S., Furberg, C. D
(2009). Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart
95: 1-3
[Full Text]
Gattellari, M., Worthington, J., Zwar, N.
(2009). Warfarin: An Inconvenient Truth. Stroke
40: 5-7
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
32: 193-203
[Abstract][Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association . Diabetes Care
32: 187-192
[Full Text]
Lawler, F. H.
(2009). Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. Mayo Clin Proc.
84: 34-36
[Full Text]
Sheehy, A. M., Coursin, D. B., Gabbay, R. A.
(2009). Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clin Proc.
84: 38-42
[Full Text]
American Diabetes Association,
(2009). Standards of Medical Care in Diabetes--2009. Diabetes Care
32: S13-S61
[Full Text]
Jenkins, D. J. A., Kendall, C. W. C., McKeown-Eyssen, G., Josse, R. G., Silverberg, J., Booth, G. L., Vidgen, E., Josse, A. R., Nguyen, T. H., Corrigan, S., Banach, M. S., Ares, S., Mitchell, S., Emam, A., Augustin, L. S. A., Parker, T. L., Leiter, L. A.
(2008). Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial. JAMA
300: 2742-2753
[Abstract][Full Text]
Previous
